Zhongtong Finance APP learned that Luye Pharma (02186) opened more than 3%, as of press time, the increase was 3.15%, trading at HKD 2.95, with a turnover of HKD 995,600.

On the news front, Luye Pharma announced that its independently developed innovative microsphere preparation, Jinyouping (rohitigotine microspheres for injection), as a variety included in the priority review and approval procedure, has obtained the listing approval of the State Drug Administration for the treatment of Parkinson's disease. It is reported that Jinyouping is the world's first long-acting sustained-release microsphere preparation for the treatment of Parkinson's disease, and it is also currently more in line with the concept of "continuous dopamine stimulation (CDS)". Weekly preparation.

Tianfeng Securities previously pointed out that considering the outstanding advantages of the company's new products, there will be multiple drugs on the market, and the market space for the main products of the core business is large, bullish on the company's development. In 2024, it is expected to usher in multiple products approved for listing, including Lubiteliding, Hydrocortisone-Naloxone, Rosuvastatin microspheres, Paliperidone microcrystals, Boluojia (Dishu monomer).